@SLScience_SLBT

SL Science (Nasdaq: SLBT) is scaling the future of cell therapy through its GDT (γδ T Cell) platform, making innovative immunotherapy more accessible worldwide.

Joined June 2026
  • Tweets35
  • Following11
  • Followers15
15Media
Preclinical data” and “IND” mean different things depending on where they fall on a cell therapy’s road to patients. About six steps, and many candidates don’t make it all the way. Ours are at the first stage, preclinical. 👉See more: slbtgroup.com/ #SLScience #SLBT
18
Meet SL Science: we develop cell therapies that harness immune cells to target cancer, centered on γδ T cells from our licensed GDT platform and designed to be "off-the-shelf." Nasdaq: SLBT 👉 Learn more: slbtgroup.com/ #SLScience #SLBT
1
45
New preclinical data at JCA2026 (Kyoto): unmodified γδ T cells from our licensed GDT platform target chemotherapy-resistant glioblastoma cells in experimental models. #SLScience #SLBT #Glioblastoma
1
41
New preclinical data: SL Science's licensed GDT platform shows γδ T cells can target the MGMT-positive glioblastoma cells that survive chemo. Presented at #JCA2026. 👉 See More: pse.is/9naggd
1
47
New FDA DMF #044612 covers our GDT-derived exosomes — now both the cells and exosomes each have their own registered filing. #SLScience #SLBT
1
1
83
Exosomes can cross the blood-brain barrier where whole cells can't, and preclinical data shows they trigger tumor cell death + work synergistically with radiotherapy. 👉 Read the full press release: pse.is/9jz2cx

From Cells to Exosomes: A New Regulatory Milestone

SL Science highlights a new FDA Drug Master File (DMF #044612) for GDT cell-derived exosomes, extending its regulatory foundation and addressing blood-brain barrier delivery in glioblastoma.

slbtgroup.com
1
33
🔔 Today, SL Science leadership rang the Closing Bell at Nasdaq MarketSite in New York, marking our first appearance at Nasdaq since our listing on June 15, 2026. #SLScience #SLBT #GammaDeltaT #CellTherapy
1
2
70
We remain focused on advancing our Gamma Delta (γδ) T cell platform across scientific, academic, and regulatory fronts — exploring its potential as a complementary approach to cancer treatment. 👉 Read the full press release: pse.is/9kgzht

Behind the Bell: SL Science's First Quarter on the γδT Cell Platform

From a licensed platform to FDA Drug Master Files, SL Science's active first quarter is the real story behind the Nasdaq bell.

slbtgroup.com
1
2
104
We're heading to Nasdaq! 🔔 SL Science (Nasdaq: SLBT) celebrates our Closing Bell Ceremony at Nasdaq MarketSite, NYC on Sept 2, 2026 (ET). Can't join in person? Tune in to our livestream — link coming soon. #SLScience #NasdaqListed #SLBT
1
2
70
🎥 Watch our Nasdaq Closing Bell Ringing Ceremony live here: nasdaq.com/marketsite/bell-r…

Bell Ringing Ceremony

nasdaq.com
1
38
30 years. Major trials. Billions invested. Glioblastoma survival rates have barely moved. Three structural barriers have defeated every therapy thrown at it: 🔴 GBM engineers its own immune shield 🔴 Blood-brain barrier blocks most drugs 🔴 Tumor heterogeneity drives resistance
1
1
39
Conventional therapies were built around immune recognition pathways that GBM has evolved to neutralize. Our GDT platform addresses all three at the mechanistic level — and these preclinical findings are building the scientific foundation for what comes next. #Glioblastoma #GDT
1
1
24
📚 References: ¹ Cancer Research, Statistics, and Treatment (2024) ² Frontiers in Immunology (2025) ³ MDPI Cancers (2026) ⁴ MDPI Future Pharmacology (2025) ⁵ MDPI Cancers (2024)
4
New peer-reviewed paper: SL Science leadership + Taipei Medical University clinical researchers outline a rigorous development framework for γδ T cell therapy in glioblastoma. 📄 Full paper: doi.org/10.3390/biomedicines… #SLScience #Glioblastoma #CellTherapy
1
3
38
✓ Broad stress-signal recognition ✓ Off-the-shelf manufacturing potential ✓ Clear roadmap for future trials 👉 Read the full press release: pse.is/9g88ug

A New Possibility for Off-the-Shelf Cell Therapy

SL Science leadership and Taipei Medical University co-author a peer-reviewed γδ T cell therapy glioblastoma framework, covering off-the-shelf manufacturing and localized brain delivery. Read the...

slbtgroup.com
2
15
🧠 Why does immunotherapy work wonders in most cancers, but barely touch glioblastoma? GBM — median survival 15 months¹ — actively blinds immune cells before they can attack.² Conventional therapies depend on recognition pathways GBM can simply turn off.³
1
2
20
γδ T cells (GDT) bypass GBM's defenses by detecting stress signals tumors can't hide — no MHC recognition required.⁴ These preclinical findings are building the scientific foundation for what comes next.
1
2
9
📚 References: ¹ Egyptian Journal of Neurosurgery (2024) doi.org/10.1186/s41984-024-0… ² Frontiers in Immunology (2025) doi.org/10.3389/fimmu.2025.1… ³ MDPI Cancers (2025) doi.org/10.3390/cancers17071… ⁴ MDPI Cancers (2023) doi.org/10.3390/cancers15245…

Survival rate of patient with glioblastoma: a population-based study

Egyptian Journal of Neurosurgery - Glioblastoma, as the most common and lethal primary malignant brain tumor, has estimated mean survival of 15 months. GBM is reported more in men. Malignant glioma...

link.springer.com
1
8
🧠 WorldBrainDay 2026: "Brain Health: Access for All" 3.4 billion people live with neurological conditions. Glioblastoma — one of the deadliest brain tumors — remains unsolved. Last week at #WCP2026 Melbourne, we took a step forward. 🔗 See More: user194977.pse.is/9crf9r
1
2
130
$SLBT + Taipei Medical University, JY BioMed & HeXun Biosciences presented preclinical γδ T-cell data: ✅ Complete tumor eradication by Day 26 ✅ Dose-dependent suppression ✅ Clean safety profile
1
2
150
"This research underscores the tremendous therapeutic potential of our γδ T-cell platform to combat challenging solid tumors like glioblastoma." — William Wang, Chairman & CEO #WorldBrainDay #WCP2026 #Glioblastoma #CellTherapy
1
63
Load more